


Randall E. Harris

EPIDEMIOLOGY OF CHRONIC DISEASE

Global Perspectives

SECOND EDITION



Randall E. Harris, MD, PhD

Professor, Colleges of Public Health and Medicine
Director, Center of Molecular Epidemiology & Environmental Health
Division of Epidemiology & Departments of Pathology & Emergency Medicine
The Ohio State University Wexner Medical Center
Columbus, Ohio

EPIDEMIOLOGY OF CHRONIC DISEASE

Global Perspectives

SECOND EDITION



JONES & BARTLETT
LEARNING



World Headquarters

Jones & Bartlett Learning
5 Wall Street
Burlington, MA 01803
978-443-5000
info@jblearning.com
www.jblearning.com

Jones & Bartlett Learning books and products are available through most bookstores and online booksellers. To contact Jones & Bartlett Learning directly, call 800-832-0034, fax 978-443-8000, or visit our website, www.jblearning.com.

Substantial discounts on bulk quantities of Jones & Bartlett Learning publications are available to corporations, professional associations, and other qualified organizations. For details and specific discount information, contact the special sales department at Jones & Bartlett Learning via the above contact information or send an email to specialsales@jblearning.com.

Copyright © 2020 by Jones & Bartlett Learning, LLC, an Ascend Learning Company

All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without written permission from the copyright owner.

The content, statements, views, and opinions herein are the sole expression of the respective authors and not that of Jones & Bartlett Learning, LLC. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not constitute or imply its endorsement or recommendation by Jones & Bartlett Learning, LLC and such reference shall not be used for advertising or product endorsement purposes. All trademarks displayed are the trademarks of the parties noted herein. *Epidemiology of Chronic Disease: Global Perspectives, Second Edition* is an independent publication and has not been authorized, sponsored, or otherwise approved by the owners of the trademarks or service marks referenced in this product.

There may be images in this book that feature models; these models do not necessarily endorse, represent, or participate in the activities represented in the images. Any screenshots in this product are for educational and instructive purposes only. Any individuals and scenarios featured in the case studies throughout this product may be real or fictitious, but are used for instructional purposes only.

The authors, editor, and publisher have made every effort to provide accurate information. However, they are not responsible for errors, omissions, or for any outcomes related to the use of the contents of this book and take no responsibility for the use of the products and procedures described. Treatments and side effects described in this book may not be applicable to all people; likewise, some people may require a dose or experience a side effect that is not described herein. Drugs and medical devices are discussed that may have limited availability controlled by the Food and Drug Administration (FDA) for use only in a research study or clinical trial. Research, clinical practice, and government regulations often change the accepted standard in this field. When consideration is being given to use of any drug in the clinical setting, the health care provider or reader is responsible for determining FDA status of the drug, reading the package insert, and reviewing prescribing information for the most up-to-date recommendations on dose, precautions, and contraindications, and determining the appropriate usage for the product. This is especially important in the case of drugs that are new or seldom used.

15101-5

Production Credits

VP, Product Management: Amanda Martin
Director of Product Management: Cathy Esperti
Product Manager: Sophie Fleck Teague
Product Specialist: Carter McAlister
Senior Project Specialist: Vanessa Richards
Project Specialist: Robert Furrrier
Senior Marketing Manager: Susanne Walker
Manufacturing and Inventory Control Supervisor: Amy Bacus
Composition: codeMantra U.S. LLC

Project Management: codeMantra U.S. LLC
Cover Design: Kristin E. Parker
Rights & Media Specialist: Maria Maimone
Media Development Editor: Shannon Sheehan
Cover Image (Title Page, Section Opener, Chapter Opener):
© Andrew Brookes/Getty Images
Printing and Binding: LSC Communications
Cover Printing: LSC Communications

Library of Congress Cataloging-in-Publication Data

Names: Harris, Randall E., author.

Title: *Epidemiology of chronic disease: global perspectives* / Randall E. Harris, MD, PhD, Director, Center of Molecular Epidemiology and Environmental Health College of Public Health, Division of Epidemiology The Ohio State University Medical Center, College of Medicine, Departments of Emergency Medicine & Pathology The Ohio State University Medical Center, Columbus, Ohio.

Description: Second edition. | Burlington, MA: Jones & Bartlett Learning, [2020] | Includes bibliographical references and index.

Identifiers: LCCN 2018059324 | ISBN 9781284151015 (paperback: alk. paper)

Subjects: LCSH: Chronic diseases—Epidemiology. | World health—Statistics.

Classification: LCC RA644.5 .H37 2020 | DDC 616/.044—dc23

LC record available at <https://lccn.loc.gov/2018059324>

6048

Printed in the United States of America

23 22 21 20 19 10 9 8 7 6 5 4 3 2 1

Contents

Preface xv
Contributors xvii

SECTION I Epidemiologic Transition and Epidemiology of Cardiovascular Diseases 1

Chapter 1 Global Epidemiology of Chronic Diseases: The Epidemiologic Transition 3

Global Pandemic of Chronic Diseases 3
Increase in World Population 4
Aging of the World Population 4
Increasing Longevity (Life Expectancy) 4
Gender Differences in Longevity 6
Aging and Disease 7
Aging of Human Cell Populations 7
Free Radical Theory of Aging 8
Telomere Shortening and Aging 9
Declining Fertility Rate in Women 9
Chromosomal Aneuploidy and Ovarian Reserve ... 11
Epidemiologic Transition 11
Global Death Rates 12
Global Epidemiology of Disease 13
Body Mass and All-Cause Mortality 19
Disability-Adjusted Life Years (DALY) 19

Chapter 2 Global Epidemiology of Cardiovascular Disease 27

Introduction 27
Spectrum of Cardiovascular Disease 28
Declining Mortality from Cardiovascular Disease in Developed Countries 31
United States Mortality from Cardiovascular Disease 31

Epidemic of Congestive Heart Failure in the United States 32
Gender and Ethnic Differences in Cardiovascular Disease in the United States 32
Epidemiologic Transition of Cardiovascular Disease 33
Risk Factors for Cardiovascular Disease 34
Primary Prevention of Cardiovascular Disease 35
Tertiary Prevention of Cardiovascular Disease 35
Global Prevention of Cardiovascular Disease 35

Chapter 3 Epidemiology of Ischemic (Coronary) Heart Disease 37

Definition of Ischemic/Coronary Heart Disease 37
Sudden Cardiac Death and Myocardial Infarction in Ischemic Heart Disease 37
Global Epidemiology of Ischemic/Coronary Heart Disease 38
Atherogenesis and Atherosclerosis 39
Other Mechanisms of Ischemic/Coronary Heart Disease 41
Historical Perspectives of the Epidemiology of Ischemic/Coronary Heart Disease 41
Risk Factors for Ischemic/Coronary Heart Disease ... 42
Prevention of Ischemic/Coronary Heart Disease ... 49

Chapter 4 Epidemiology of Myocardial Infarction 57

Function of the Heart 57
Clinical Parameters of Myocardial Infarction (Heart Attack) 59
Global Mortality and Morbidity Due to Myocardial Infarctions 60
Time Trends in Myocardial Infarction Rates 60
Risk Factors for Myocardial Infarction 62
The INTERHEART Study of Acute Myocardial Infarction 63
Seven Countries Study of Myocardial Infarction ... 64

Framingham Study of Myocardial Infarction.....65
 Primary Prevention of Myocardial Infarction.....65

Chapter 5 Epidemiology of Sudden Cardiac Death..... 75

Introduction.....75
 Definition of Sudden Cardiac Death.....75
 Determining the Causes of Sudden Cardiac Death75
 Age Distribution and Causes of Sudden Cardiac Death76
 Causes of Sudden Cardiac Death in Adults76
 Ischemic Heart Disease, Myocardial Infarction, and Sudden Cardiac Death77
 Heart Failure and Sudden Cardiac Death77
 Atrial Fibrillation and Sudden Cardiac Death77
 Cardiomyopathy among Adults.....77
 Causes of Sudden Cardiac Death in Children and Adolescents78
 Connective Tissue Disease78
 Congenital and Inherited Anomalies of the Heart....78
 Trauma79
 Overall Mortality (Incidence) of Sudden Cardiac Death.....79
 Declining Trends in Sudden Cardiac Death.....80
 Risk Factors and Predisposing Conditions for Sudden Cardiac Death in Adults80
 The Trigger-Substrate Hypothesis of Sudden Cardiac Death81
 Surviving “Out-of-Hospital” Sudden Cardiac Arrest81
 Prevention of Sudden Cardiac Arrest and Death....82

Chapter 6 Epidemiology of Stroke (Cerebral Infarction)..... 85

Ischemic and Hemorrhagic Strokes85
 Vascular Network of the Brain.....86
 Global Mortality of Stroke.....87
 Decline in Stroke Mortality in Developed Nations.....88
 Racial Differences in Stroke Mortality in the United States.....89
 Risk Factors for Stroke.....90
 Prevention of Stroke98

Chapter 7 Epidemiology of Heart Failure... 105

Introduction..... 105
 Definition of Heart Failure..... 105
 Systolic Heart Failure..... 106
 Diastolic Heart Failure..... 106
 Cor Pulmonale and Right-Sided Heart Failure..... 106
 The Framingham Heart Study: Incidence and Prevalence of Heart Failure 106
 The Rotterdam Heart Study 106
 United States Trends in Heart Failure 107
 The Epidemic of Hospitalizations for Heart Failure..... 108
 Mortality of Heart Failure..... 109
 Diseases Predisposing to Heart Failure 109
 Behavioral Risk Factors for Heart Failure 111
 Race and Gender Differences in Heart Failure 113
 Heart Failure and Ejection Fractions..... 114
 Primary Prevention of Heart Failure 114
 Secondary Prevention of Heart Failure 114
 Therapy and Tertiary Prevention for Patients with Heart Failure 115

Chapter 8 Epidemiology of Aortic Aneurysm and Dissection..... 119

Introduction..... 119
 Pathogenesis of Aortic Aneurysm, Dissection, and Rupture..... 119
 Thoracic Versus Abdominal Aortic Aneurysms ... 119
 Aortic Dissection or Rupture 120
 Incidence of Thoracic Aortic Aneurysm and Dissection..... 121
 Trends in Mortality from Aortic Aneurysm and Dissection..... 121
 Gender Differences in Prevalence of Thoracic Aneurysms 123
 Causes and Risk Factors of Aortic Aneurysms.... 123
 Atherosclerosis Versus Genetics: Thoracic Aortic Aneurysms 124
 Bicuspid Aortic Valve and Ascending Thoracic Aortic Aneurysm 124
 Connective Tissue Disorders and Thoracic Aortic Aneurysms 125
 Infection and Aortic Aneurysm 125

Peripheral Artery Disease and Abdominal
 Aortic Aneurysms 125
 Mortality from Peripheral Artery Disease 126
 Other Risk Factors for Aortic Aneurysm,
 Dissection, and Rupture 126
 Prevention and Screening 127

Chapter 9 Epidemiology of Venous Thromboembolism and Pulmonary Embolism 129

Introduction 129
 Venous Thromboembolism 129
 Incidence of Venous Thromboembolism 131
 Trends in Mortality and Case Fatality from
 Pulmonary Embolism 131
 Risk Factors and Predisposing Conditions
 for Venous Thromboembolism 132
 Exogenous Estrogens and Venous
 Thromboembolism 133
 Genetic Predisposition to Venous
 Thromboembolism 133
 Cardiovascular Risk Factors and Venous
 Thromboembolism 134
 Prevention of Venous Thromboembolism 134

Chapter 10 Epidemiology of Hypertension 137

Introduction 137
 Clinical Definition of Hypertension 137
 Global Epidemiology of Hypertension 139
 Hypertensive Heart Disease 139
 Atherosclerosis, Hypertension,
 and Cardiovascular Disease 140
 Ecological Patterns of Hypertension 140
 Hypertension in the United States Stroke Belt 141
 Ethnicity and Hypertension in the United States 141
 Time Trends of Hypertension in
 the United States 142
 Time Trends of Hypertension in India 143
 Physiological Control of Blood Pressure 143
 Essential Hypertension 144
 Secondary Hypertension 145
 Hypertension of Pregnancy (Preeclampsia) 145
 Risk Factors for Essential Hypertension 145

Tobacco and Hypertension 149
 Insulin Resistance, Diabetes Mellitus, and
 Hypertension 149
 The Metabolic Syndrome (Syndrome X) 151
 Genetics of Hypertension 151
 Prevention of Hypertension 152

SECTION II Epidemiology of Cancer 159

Chapter 11 Pathogenesis of Cancer 161

Biological Basis of Cancer 161
 Evolution of Cancer 161
 Cell Division (Mitosis) and Cancer 161
 Cancer and the Cell Cycle 162
 Life Spans of Human Cells 163
 Turnover of Human Cells 164
 Evolution of Cancer in the Human Host 164
 Theories of Carcinogenesis 166
 Molecular Mechanisms of Carcinogenesis 167

Chapter 12 Global Epidemiology of Cancer 177

Global Burden of Cancer 177
 Global Burden of Cancer in Men and Women 178
 Histological Profile of Global Cancer 179
 Global Trends in Cancer 179
 Cancer in Developing Versus
 Developed Nations 181
 Cancer Mortality in the United States 183
 Epidemiologic Transition of Cancer 185
 Web of Causation of Cancer 185
 Lifestyle and Environment in Cancer
 Development 187
 Tobacco and Cancer 188
 1964 U.S. Surgeon General's Report
 on Smoking and Health 188
 Diet and Cancer 190
 Alcohol and Cancer 191
 Infection and Cancer 191
 Global Cancer Prevention and Control 191
 Cancer Education 193

Chapter 13 Epidemiology of Lung Cancer . . . 197

Anatomy and Function of the Lungs	197
Global Burden of Lung Cancer	197
Global Lung Cancer Incidence and Mortality	198
Cigarette Smoking and Lung Cancer	199
Cigarette Smoking and Lung Cancer Mortality in the United States	200
Smoking and Histologic Changes in Lung Tissues	201
Transition of Lung Cancer Cell Types	201
Cigarette Smoking and Lung Cancer Histology	202
Tobacco Carcinogenesis	202
Chronic Obstructive Pulmonary Disease and Lung Cancer	203
Lung Cancer Risk Factors Other Than Tobacco	204
Lung Cancer Diagnosis, Treatment, and Survival	208
Primary Prevention of Lung Cancer	209
Nonsteroidal Anti-inflammatory Drugs and Lung Cancer	209
Smoking Cessation and Lung Cancer	210
Electronic Cigarettes (E-cigarettes)	211

Chapter 14 Epidemiology of Laryngeal Cancer 215

Anatomy of the Larynx	215
Histology	215
Global Epidemiology	215
Laryngeal Cancer in the United States	215
Age at Diagnosis of Laryngeal Cancer	216
Risk Factors for Laryngeal Cancer	216
Primary Prevention of Laryngeal Cancer	222

Chapter 15 Epidemiology of Cancers of the Lip, Oral Cavity, and Pharynx . . . 225

Anatomy of the Oral Cavity	225
Premalignant Lesions of the Oral Cavity	226
Oral Cavity Cancer Risk Factors	227
Cancer of the Oropharynx and Laryngopharynx	232
Cancer of the Nasopharynx	232

Chapter 16 Epidemiology of Esophageal Cancer 239

Anatomy and Function of the Esophagus	239
Global Epidemiology of Esophageal Cancer	239
Pathogenesis of Esophageal Cancer	241
Risk Factors for Esophageal Cancer	241
Risk Factors for Squamous Cell Carcinomas of the Esophagus	242
Risk Factors for Barrett's Esophagus and Esophageal Adenocarcinoma	242
Genetic Risk Factors for Esophageal Cancer	242
Prevention of Esophageal Cancer	243

Chapter 17 Epidemiology of Stomach Cancer 245

Anatomy and Function of the Stomach	245
Global Epidemiology of Stomach Cancer	246
Stomach Cancer Prevention: Epidemiology of an Unplanned Triumph	247
<i>Helicobacter pylorus</i> and Stomach Cancer	248
Histologic and Anatomic Subtypes of Stomach Cancer	250
Genetic Predisposition to Stomach Cancer	250
Prevention of Stomach Cancer	251

Chapter 18 Epidemiology of Colorectal Cancer 253

Global Epidemiology of Colorectal Cancer	253
Pathogenesis of Colorectal Cancer	253
Risk Factors for Colorectal Cancer	254
Screening for Colorectal Cancer	260

Chapter 19 Epidemiology of Pancreatic Cancer 263

Global Epidemiology of Pancreatic Cancer	263
Pathogenesis of Pancreatic Cancer	264
Tobacco Smoking and Pancreatic Cancer	265
Alcohol and Pancreatic Cancer	266
Risk of Pancreatic Cancer: Combined Effect of Tobacco and Alcohol	266
Dietary Fat and Pancreatic Cancer	266
Chronic Pancreatitis and Pancreatic Cancer	267

Germline Mutations and Pancreatic Cancer 268
 Somatic Mutations in Pancreatic Cancer 269
 Epigenetics of Pancreatic Cancer..... 269
 Obesity, Diabetes Mellitus Type 2,
 and Pancreatic Cancer..... 269
 Islet Cell Tumors 270
 Prevention of Pancreatic Cancer 270

Chapter 20 Epidemiology of Primary Liver Cancer: Hepatocellular Carcinoma and Cholangiocarcinoma..... 273

Liver Function and Anatomy..... 273
 Hepatocellular Carcinoma
 and Cholangiocarcinoma..... 274
 Hepatocellular Carcinoma 274
 Cholangiocarcinoma 281

Chapter 21 Epidemiology of Breast Cancer..... 287

Anatomy and Function of the
 Mammary Gland 287
 Global Burden of Breast Cancer 287
 Breast Cancer Detection, Staging,
 and Survival 288
 Pathology of Breast Cancer 289
 Mechanisms of Breast Carcinogenesis..... 290
 Risk Factors for Breast Cancer 290
 Body Mass and Postmenopausal Breast
 Cancer 292
 Mammographic Breast Density and
 Postmenopausal Breast Cancer Risk..... 294
 Male Breast Cancer 295
 Prevention of Breast Cancer..... 295
 Summary of Breast Cancer Epidemiology 296

Chapter 22 Epidemiology of Ovarian Cancer..... 301

Global Epidemiology of Ovarian Cancer..... 301
 Ovarian Cancer: The “Silent Killer”..... 301
 Pathophysiology of the Human Ovary 301
 Pathogenesis of Ovarian Cancer 302
 Risk Factors for Ovarian Cancer..... 304

Protective Reproductive Factors and Ovarian
 Cancer 306
 Oral Contraceptives and Ovarian Cancer 306
 Screening for Ovarian Cancer 306

Chapter 23 Epidemiology of Cancer of the Corpus Uteri: Endometrial Cancer, Uterine Sarcoma, and Choriocarcinoma 309

Global Impact of Cancer of the Corpus Uteri 309
 Malignant Tumors of the Corpus Uteri 311
 Endometrial Cancer Versus Cervical Cancer:
 Cellular Origins 311
 Trends in Endometrial Cancer..... 312
 Endometrial Cancer: Postmenopausal
 Age of Onset 313
 Subtypes of Endometrial Cancer 313
 Models of Endometrial Carcinogenesis..... 313
 Risk Factors for Endometrial Cancer 315
 Summary: Epidemiology of Endometrial
 Cancer 320
 Epidemiology of Choriocarcinoma..... 322

Chapter 24 Epidemiology of Cervical Cancer..... 327

Global Burden of Cervical Cancer 327
 Early Detection of Cervical Dysplasia 327
 Pathogenesis of Cervical Cancer 329
 Risk Factors for Cervical Cancer 329
 Prevention of Cervical Cancer..... 332

Chapter 25 Epidemiology of Vaginal, Vulvar, and Anal Cancer 335

Global Burden of Vaginal, Vulvar, and
 Anal Cancer 335
 Human Papillomavirus in Vaginal, Vulvar,
 and Anal Carcinoma..... 335
 Global Pattern of Vaginal, Vulvar, and Anal
 Squamous Cell Cancers..... 337
 Human Immunodeficiency Virus in Vaginal,
 Vulvar, and Anal Carcinoma..... 337
 Epidemiology of Vaginal Cancer 338
 Epidemiology of Vulvar Cancer..... 342
 Epidemiology of Anal Carcinoma 344

Primary Prevention of HPV-Related Vaginal, Vulvar, and Anal Cancer.....	346
Screening for Squamous Cell Vaginal, Vulvar, and Anal Cancer.....	346

Chapter 26 Epidemiology of Prostate Cancer..... 351

Global Burden of Prostate Cancer.....	351
Age-Specific Risk of Prostate Cancer.....	352
Anatomy and Function of the Prostate Gland.....	354
Pathogenesis of Prostate Cancer.....	354
Finasteride and Prostate Cancer.....	355
Dietary Fat and Prostate Cancer.....	355
Genetics of Prostate Cancer.....	356
Prostate Cancer and Sexual Activity.....	357
Supplemental Antioxidants and Prostate Cancer.....	357
Nonsteroidal Anti-inflammatory Drugs and Prostate Cancer.....	357
Screening for Prostate Cancer.....	357
Zinc and Survival of Prostate Cancer.....	358

Chapter 27 Epidemiology of Testicular Cancer..... 361

Anatomy of the Testis and Spermatogenesis.....	361
Pathology of Testicular Cancer.....	361
Global Epidemiology of Testicular Cancer.....	363
Cytogenetics and Genetics of Testicular Germ Cell Tumors.....	363
Risk Factors for Testicular Cancer.....	365
Prevention and Therapy of Testicular Cancer.....	366

Chapter 28 Epidemiology of Carcinoma of the External Male Genitalia: Penis and Scrotum 369

Global Epidemiology of Penile Cancer.....	369
Penile Cancer in the United States.....	370
Age-Specific Incidence of Penile Cancer.....	371
Pathology and Histology.....	371
Risk Factors for Carcinoma of the Penis.....	371
Cancer of the Scrotum.....	374

Molecular Carcinogenesis.....	374
Preventive Strategies.....	374

Chapter 29 Epidemiology of Urinary Bladder Cancer 377

Anatomy and Function of the Urinary Bladder ...	377
Global Epidemiology of Bladder Cancer.....	377
Pathogenesis of Urinary Bladder Cancer.....	378
Risk Factors for Urinary Bladder Cancer.....	379
Prevention of Bladder Cancer.....	383

Chapter 30 Epidemiology of Kidney Cancer..... 385

Anatomy and Function of the Kidneys.....	385
Global Epidemiology of Kidney Cancer.....	385
Global Pattern of Kidney Cancer.....	387
Kidney Cancer Mortality.....	387
Types of Kidney Cancer.....	387
Pathologic Subtypes of Renal Cell Carcinoma.....	388
Risk Factors for Renal Cell Carcinoma.....	389
Risk Factors for Transitional Cell Carcinoma of the Renal Pelvis.....	392
Prevention of Kidney Cancer.....	392

Chapter 31 Epidemiology of Cancers of the Thyroid and Parathyroid 395

Thyroid Gland: Anatomy and Function.....	395
Benign Adenomas of the Thyroid Gland.....	396
Malignant Tumors of the Thyroid and Parathyroid.....	397
Global Burden of Thyroid Cancer.....	397
Trends in Papillary and Follicular Thyroid Carcinoma.....	399
Risk Factors for Thyroid Cancer.....	400
Iodine and Thyroid Function.....	405
Goitrogenic Dietary Factors and Thyroid Disorders.....	408
Medullary Thyroid Cancer.....	408
Prevention and Therapy of Thyroid Cancer.....	409
Epidemiology of Parathyroid Cancer.....	409

Chapter 32 Epidemiology of Adrenal Cancer 415

Anatomy and Function of the Adrenal Glands . . . 415
 Detection of Adrenal Tumors 415
 Adrenal Cortical Carcinoma 416
 Risk Factors for Adrenal Cortical Carcinomas 416
 Tumors of the Adrenal Medulla: Neuroblastoma and Pheochromocytoma 418
 Multiple Endocrine Neoplasia and Sipple Syndrome 420
 Summary of Adrenal Cancer Epidemiology 420

Chapter 33 Epidemiology of Malignant Melanoma 423

Global Epidemiology of Malignant Melanoma . . . 423
 Pathogenesis of Malignant Melanoma 424
 Risk Factors for Malignant Melanoma 426
 Malignant Melanoma and Parkinson’s Disease . . . 428
 Prevention of Malignant Melanoma 429

Chapter 34 Epidemiology of Nonmelanoma Skin Cancer: Basal Cell, Squamous Cell, and Merkel Cell Skin Cancers. 433

Anatomy and Function of the Skin 433
 Nonmelanoma Skin Cancer 434
 Global Burden of Nonmelanoma Skin Cancer . . . 434
 Age-Specific Incidence of Nonmelanoma Skin Cancer 435
 Global Incidence and Mortality of Nonmelanoma Skin Cancer 435
 Longitudinal Trends in Basal Cell and Squamous Cell Carcinomas of the Skin 436
 Solar Radiation and Nonmelanoma Skin Cancer . . . 438
 Risk Factors for Basal Cell Carcinoma of the Skin . . . 439
 Risk Factors for Squamous Cell Carcinoma of the Skin 440
 Genetics of Nonmelanoma Skin Cancer 443
 Immunosuppression and Skin Cancer 445
 Inflammogenesis of Skin Cancer 445
 Risk of Multiple Basal Cell or Squamous Cell Carcinomas of the Skin 446

Vitamin D and Skin Cancer 446
 Epidemiology of Merkel Cell Carcinoma 446
 Environmental Prevention of Skin Cancer 447
 Behavioral Prevention of Skin Cancer 447

Chapter 35 Epidemiology of Classic Sarcoma and Kaposi Sarcoma 453

Classification of Sarcoma 453
 Global Epidemiology of Sarcoma 453
 Sarcoma in the U.S. Population 453
 Epidemiology of Pediatric Sarcomas 455
 Epidemiology of Adult Sarcomas 459
 Cyclooxygenase-2 in Sarcomas 468
 Prevention and Control of Kaposi Sarcoma 468
 Prevention and Treatment of Other Sarcomas 469

Chapter 36 Epidemiology of Lymphoma: Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma, and Multiple Myeloma 473

Classification of Lymphoma 473
 Epidemiology of Non-Hodgkin’s Lymphoma 474
 Gender and Ethnic Differences in Non-Hodgkin’s Lymphoma 477
 Risk Factors for Non-Hodgkin’s Lymphoma 477
 Epidemiology of Hodgkin’s Lymphoma 485
 Risk Factors for Hodgkin’s Lymphoma 486
 Epidemiology of Multiple Myeloma 487
 Waldenström’s Macroglobulinemia 489
 Models of Pathogenesis of Lymphoma 489
 Prevention of AIDS-Related Lymphoma 489
 Summary 490

Chapter 37 Epidemiology of Leukemia 497

Classification of Leukemia 497
 Hematopoiesis 498
 Pathogenesis of Leukemia 498
 Global Epidemiology of Leukemia 499
 Incidence and Mortality of Leukemia Subtypes . . . 501
 Trends in Leukemia Incidence and Survival 501

Pediatric Leukemia: Trends in Incidence and Mortality 502
 Adult Leukemia..... 507
 Prevention and Control of Leukemia 513

Chapter 38 Epidemiology of Brain Tumors: Glioma, Meningioma, Acoustic Neuroma, and Pituitary Tumors 517

Global Epidemiology of Brain Tumors 517
 Brain Tumors in the United States..... 518
 Classification of Brain Tumors 519
 U.S. Study of Brain Tumors 526
 Genetic Anomalies and Brain Tumors 526
 Oligodendroglioma..... 528
 Risk Factors for Meningiomas 528
 Pituitary Tumors 530
 Primary Lymphoma of the Brain 530
 Brain Tumors in Children..... 531
 Therapeutic Approaches to Glioma and Other Brain Tumors 531

SECTION III Epidemiology of Chronic Respiratory, Metabolic, and Musculoskeletal Diseases 537

Chapter 39 Epidemiology of Chronic Obstructive Pulmonary Disease 539

Introduction..... 539
 Anatomy and Function of the Lungs..... 539
 Diagnosis of COPD..... 540
 Age Distribution of COPD..... 540
 Global Burden of COPD..... 541
 Trends in Mortality Rates of COPD:
 United States and Western Europe..... 542
 Pathogenesis of COPD..... 542
 Underdiagnosis of COPD 549
 Population Attributable Fraction:
 Smoking and COPD 549

Pneumonia and COPD..... 549
 HIV and COPD..... 550
 Lung Cancer and COPD..... 550
 Case Fatality of COPD Exacerbation 550
 Prevention of COPD 550
 Smoking Cessation in COPD Patients..... 551
 Control of Air Pollution 552
 Global Alliance Against Chronic Respiratory Diseases..... 552

Chapter 40 Epidemiology of Asthma 555

Clinical Diagnosis of Asthma..... 555
 Global Burden of Asthma 556
 Global Studies of Asthma in Children and Adults... 556
 Asthma in Children 556
 Asthma in Adults 557
 Global Initiative for Asthma 557
 The Hygiene Hypothesis of Asthma..... 559
 Risk Factors of Asthma..... 560
 Atopy and Asthma..... 560
 Respiratory Viruses and Asthma..... 562
 Environmental Tobacco Smoke and Asthma 562
 Atopy, Environmental Tobacco Smoke, and Asthma..... 563
 Food Allergy and Asthma..... 563
 Asthma and Obesity..... 563
 Asthma and Household Cleaning Products 564
 Drug-Induced Asthma..... 564
 Vaccination and Childhood Asthma..... 565
 Genetics of Asthma..... 565
 Preventing Asthma Progression: Avoidance of Environmental Tobacco Smoke..... 566
 Risk Factors for Fatal Asthma Attack 566
 Therapy for the Asthmatic Patient..... 566
 Summary..... 567

Chapter 41 Epidemiology of Diabetes Mellitus 571

Introduction..... 571
 Historical Summary of Diabetes Mellitus 571
 Role of Insulin in Diabetes 572
 Diagnosis of Diabetes..... 573

Types of Diabetes..... 574
 Global Pandemic of Diabetes Mellitus..... 574
 Global Prevalence of Diabetes 575
 Distribution of Diabetes by Gender and Age 576
 Global Deaths Attributable to Diabetes 576
 Disability-Adjusted Life Years for Diabetes..... 578
 Burden of Diabetes in the United States..... 578
 Mortality from Diabetes in the United States 579
 Population-Based Models of Diabetes..... 580
 The Health Impact of Diabetes..... 581
 Diabetic Ketoacidosis 582
 Microvascular Complications of Diabetes 582
 Macrovascular Complications of Diabetes..... 582
 Epidemiology of Type 1 Diabetes 583
 Risk Factors for Type 1 Diabetes 585
 Birth Weight and Type 1 Diabetes 587
 Accelerator Hypothesis of Type 1 Diabetes 588
 Treatment for Type 1 Diabetes 588
 Prediabetes..... 588
 Type 2 Diabetes 589
 Risk Factors for Type 2 Diabetes 589
 The Metabolic Syndrome (Syndrome X)..... 596
 Gestational Diabetes..... 598
 Type 2 Diabetes in Children and
 Adolescents 598
 Double Diabetes 598
 Economic Impact of Diabetes..... 599
 Prevention of Diabetes Mellitus 599
 Screening for Gestational Diabetes..... 600
 Tertiary Prevention of Microvascular/
 Macrovascular Complications of Diabetes..... 600
 Summary..... 600

Chapter 42 Epidemiology of Obesity 609

Introduction..... 609
 Classification of Overweight and
 Obesity in Adults 610
 Limitations of the BMI 610
 Global Burden of Adult Obesity 612
 Global Prevalence of Adult Obesity 612
 Gender Differences in Obesity 614
 Urban Versus Rural Differences in Obesity 614

Prevalence of Adult Obesity in the
 United States 615
 Distribution of Obesity by Age, Gender,
 and Ethnicity in the United States..... 615
 Health Consequences of Obesity 616
 Obesity and Total Mortality 616
 Obesity and Type 2 Diabetes..... 617
 Obesity and Cardiovascular Disease..... 618
 Obesity and Cancer..... 619
 Obesity and GERD 621
 Obesity and Obstructive Sleep Apnea..... 622
 Obesity and Osteoarthritis 623
 Obesity and Quality of Life..... 623
 Mechanisms of Pathogenesis
 in Obesity-Related Diseases..... 624
 Obesity and Atherogenesis 625
 Obesity and Insulin Resistance..... 626
 Overview of Adipocyte Regulatory Processes 626
 Fat Storage (Lipogenesis) 627
 Fat Breakdown (Lipolysis) 627
 Secretion of Adipokines by Adipocytes 627
 Fat Cell Size, Number, and Turnover in
 Humans..... 628
 Brown Adipose Tissue 629
 Risk Factors of Obesity 629
 Genetics of Obesity..... 630
 Environmental Factors Contributing
 to Obesity 630
 Childhood Obesity 631
 The Burden of Childhood Obesity..... 632
 Risk Factors in Early Life and the
 Development of Later Obesity 633
 Prevention of Obesity..... 634
 Therapy of Obesity 635
 Liposuction..... 636
 Bariatric Surgery 636
 Summary..... 637

**Chapter 43 The Epidemiology of Thyroid
 Disease: *Hyperthyroidism*
 and *Hypothyroidism* 647**

Thyroid Gland: Anatomy and Function..... 647
 Diseases of the Thyroid Gland..... 648

Prevalence and Incidence of Hyperthyroidism and Hypothyroidism. 648

Rare Medical Emergencies of Thyroid Dysfunction 649

Mortality Rates of Hyperthyroidism and Hypothyroidism. 649

Hyperthyroidism. 650

Graves' Disease 651

The Human Leukocyte Antigen Locus and Autoimmune Thyroiditis 652

Hashimoto's Thyroiditis 653

Iatrogenic Hyperthyroidism. 654

Exogenous Hyperthyroidism. 654

Hypothyroidism 654

Cretinism 655

Goitrogenic Dietary Factors and Thyroid Disorders. 656

Global Impact of Iodine Deficiency 656

Hypothyroidism in Iodine-Replete Nations. 657

Iodine Deficiency in Pregnancy 657

Prevention of Thyroid Dysfunction 657

Chapter 44 Epidemiology of Chronic Kidney Disease 661

Anatomy and Function of the Kidneys 661

Glomerular Filtration Rate. 661

Diagnosis of Chronic Kidney Disease. 662

Epidemiologic Transition of Chronic Kidney Disease 663

Global Burden of Chronic Kidney Disease 663

Cardiovascular Deaths and Chronic Kidney Disease. 664

Global Pattern of Chronic Kidney Disease: Mortality 664

Chronic Kidney Disease in Developing Countries. 664

Chronic Kidney Disease in Developed Countries. 666

Causation of Chronic Kidney Disease. 667

Diabetic Nephropathy 667

Hypertensive Nephropathy 668

Chronic Glomerulonephritis 669

Blood Lipids, Cholesterol, and Chronic Kidney Disease 670

Obesity and Chronic Kidney Disease 671

Smoking and Chronic Kidney Disease. 672

Alcohol Abuse, Gout and Kidney Disease 673

Chronic Kidney Disease in Children and Adolescents 673

Prevention of Chronic Kidney Disease. 674

Tertiary Prevention of Chronic Kidney Disease. 674

Dialysis and Renal Transplantation for End-Stage Renal Disease. 674

Hemodialysis for End-Stage Renal Disease 675

Renal Transplant for End-Stage Renal Disease 675

Peritoneal Dialysis for End-Stage Renal Disease. 675

Chapter 45 Epidemiology of Cirrhosis of the Liver. 681

Global Burden of Cirrhosis of the Liver 681

Liver Function and Anatomy. 682

Cirrhosis of the Liver: Pathology, Clinical Symptoms, and Diagnosis 684

Pathogenesis of Cirrhosis of the Liver 684

Prevention of Viral Hepatitis. 699

Conclusion 700

Chapter 46 Epidemiology of Osteoporosis. . . 707

Introduction. 707

Discovery. 707

Pathogenesis of Osteoporosis. 707

Diagnosis of Osteoporosis 708

Bone Mineral Density and Osteoporosis. 708

Incidence and Prevalence of Hip Fracture 708

Survival and Mortality: Hip Fractures 709

Global Burden of Osteoporosis. 710

Risk Factors for Osteoporosis. 711

Primary Prevention of Osteoporosis. 721

Chapter 47 Epidemiology of Arthritis 727

Introduction. 727

Synovial Joints. 727

Pathogenesis of Arthritis. 728

Osteoarthritis (Degenerative Joint Disease) 728

Diagnosis of Osteoarthritis. 729

Age-Specific Incidence and Prevalence of Osteoarthritis 729

Disability in Osteoarthritis 730

Trends in Osteoarthritis Prevalence 730

Prevention of Osteoarthritis 733

Rheumatoid Arthritis 734

Disability in Rheumatoid Arthritis 734

Gout 738

Ankylosing Spondylitis 744

Juvenile Idiopathic Arthritis 745

Suppurative (Septic) Arthritis 747

SECTION IV Epidemiology of Neurological Diseases 751

Chapter 48 Epidemiology of Alzheimer’s Disease 753

Introduction 753

Diagnosis and Progression of Alzheimer’s Disease 753

Age-Specific Incidence of Alzheimer’s Disease ... 754

Global Incidence of Alzheimer’s Disease 755

Global Prevalence of Alzheimer’s Disease 755

Alzheimer’s Disease: Survival and Case Fatality 755

Alzheimer’s Disease: Global Mortality 756

Alzheimer’s Disease: Disability-Adjusted Life Years 758

Burden of Alzheimer’s Disease in the United States 758

Pathology of Alzheimer’s Disease 759

Risk Factors of Alzheimer’s Disease 760

Genetics of Alzheimer’s Disease 766

Vascular Dementia 767

Lewy Body Dementia 767

Mixed Forms of Dementia 768

Prevention of Dementia 769

Chapter 49 Epidemiology of Parkinson’s Disease 775

Introduction 775

History of Parkinson’s Disease 775

Pathology of Parkinson’s Disease 777

Incidence and Prevalence of Parkinson’s Disease 777

Global Incidence of Parkinson’s Disease 779

Global Age-Specific Prevalence of Parkinson’s Disease 780

Survival, Dementia, and Mortality in Parkinson’s Disease 780

Parkinson’s Disease: Trends in Global Mortality and Prevalence 781

Disability-Adjusted Life Years: Parkinson’s Disease 781

Causes of the Rising Global Burden of Parkinson’s Disease 783

Risk Factors for Parkinson’s Disease 783

Tertiary Prevention in Parkinson’s Disease 787

Chapter 50 Epidemiology of Multiple Sclerosis 791

Introduction 791

Discovery of Multiple Sclerosis 791

Diagnosis of Multiple Sclerosis 792

Course of Multiple Sclerosis 792

Global Burden of Multiple Sclerosis 792

Global Prevalence and Incidence of Multiple Sclerosis 793

Age-Specific Incidence of Multiple Sclerosis 794

Case Fatality and Life Expectancy 794

Suicide in Multiple Sclerosis 795

Global Mortality: Multiple Sclerosis 795

Autoimmunity and Multiple Sclerosis 796

Pathogenic Mechanisms in Multiple Sclerosis ... 796

Prevention and Therapy of Multiple Sclerosis 801

Chapter 51 Epidemiology of Epilepsy 805

Introduction 805

Diagnosis of Epilepsy 805

Types of Seizures 805

Types of Epilepsy 807

Epilepsy Syndromes 808

Febrile (Fever) Seizures and Epilepsy 811

Isolated Seizures 813

Circumstantial (Situation-Related) Seizures 813

Status Epilepticus..... 813
 Global Burden of Epilepsy..... 814
 Global Prevalence of Epilepsy..... 815
 Disability-Adjusted Life Years (DALY)
 Lost from Epilepsy..... 815
 Epilepsy Mortality..... 816
 Suicide and Epilepsy..... 818
 Epilepsy Risk Factors..... 819
 Epilepsy: Treatment and Prognosis..... 822

Chapter 52 Epidemiology of Schizophrenia 827

Introduction..... 827
 Global Burden of Schizophrenia..... 827
 Global Incidence of Schizophrenia..... 828
 Global Prevalence of Schizophrenia..... 828
 Prevalence of Schizophrenia in
 the United States..... 828
 Excess Mortality from Schizophrenia..... 829
 Course of Schizophrenia..... 829
 Suicide in Schizophrenia..... 831
 Models of Pathogenesis: Schizophrenia..... 832
 Risk Factors of Schizophrenia..... 833
 Prenatal Dietary Deficiency and Schizophrenia... 836
 Primary Prevention of Schizophrenia..... 839
 Tertiary Prevention in Schizophrenia..... 839

Chapter 53 Epidemiology of Suicide..... 845

Introduction..... 845
 Global Burden of Suicide..... 845
 Gender and Suicide..... 846
 Age Distribution of Suicide..... 847
 Time Trends in Suicide Rates..... 848
 Risk Factors for Suicide..... 849

SECTION V Epidemiology of Chronic Infectious Diseases 863

Chapter 54 Epidemiology of Tuberculosis... 865

Introduction..... 865

Historical Record of Tuberculosis..... 865
 Global Burden of Tuberculosis in the
 21st Century..... 866
 Tuberculosis: Incidence, Prevalence, and
 Mortality, 2007..... 867
 Tuberculosis: Incidence, Prevalence, and
 Mortality, 2017 Update..... 868
 Disability-Adjusted Life Years: Tuberculosis..... 869
 Tuberculosis in the United States..... 870
 Transmission of Tuberculosis..... 870
 Pathogenesis of Tuberculosis..... 871
 Risk Factors for Tuberculosis..... 871
 Multidrug-Resistant Tuberculosis and
 Extensively Drug-Resistant Tuberculosis..... 875
 Antibiotic Resistance in *Mycobacterium*
 tuberculosis..... 875
 Prevention of Tuberculosis..... 875

Chapter 55 Epidemiology of Malaria 879

Introduction..... 879
 History of Malaria..... 879
 Life Cycle of Plasmodia..... 880
 Pathogenesis of Malaria..... 880
 Global Burden of Malaria..... 881
 Malaria: Incidence and Mortality,
 2013–2016 Update..... 882
 Global Incidence of *Plasmodium falciparum*:
 Controversial Findings..... 883
 Genetic Resistance to Malaria..... 885
 Control of Malaria..... 886

Chapter 56 Epidemiology of HIV/AIDS 889

Introduction..... 889
 History of HIV/AIDS..... 889
 Human Immunodeficiency Virus Life Cycle..... 890
 Global Burden of HIV/AIDS..... 890
 HIV/AIDS in Africa..... 892
 HIV/AIDS in the United States..... 893
 Origin of HIV..... 894
 Coinfections Involving HIV..... 895
 Prevention and Control of HIV/AIDS..... 898

Index 901

Preface

This second edition of *Epidemiology of Chronic Disease: Global Perspectives* is written for all students and teachers of the health sciences, particularly those in epidemiology, public health, and medicine. Its main purpose is to present current and comprehensive information on epidemiology, etiology, pathogenesis, risk factors, and preventive factors of common chronic diseases. In writing the new edition of this book, I have made liberal use of the internet and drawn upon worldwide information to address the global landscape of chronic diseases.

This new edition has 56 chapters that are organized into five distinct sections beginning with an introductory chapter on the “*epidemiologic transition*” whereby chronic diseases have replaced acute infectious conditions concurrent with improved health care and increasing longevity in many populations of the world. Subsequent sections cover cardiovascular and cerebrovascular diseases (coronary heart disease, myocardial infarction, sudden cardiac death, stroke, congestive heart failure, peripheral artery disease and aortic aneurysms, venous thromboembolism and pulmonary embolism, and hypertension), major forms of cancer (lung cancer, laryngeal cancer, head and neck cancer, esophageal cancer, stomach cancer, colon cancer, pancreatic cancer, liver cancer, breast cancer, ovarian cancer, vulvar and vaginal cancer, cervical cancer, prostate cancer, testicular cancer and other male genital cancers, bladder cancer, kidney cancer, sarcoma, malignant melanoma, lymphoma, leukemia, and brain tumors), diseases of the respiratory tract (chronic obstructive pulmonary disease and asthma), metabolic and digestive diseases (diabetes mellitus, obesity, thyroid disease, kidney disease, and liver disease), musculoskeletal diseases (osteoporosis and arthritis), neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, schizophrenia, epilepsy, multiple sclerosis, and suicide), and finally three major infectious diseases (tuberculosis, malaria, and HIV disease) that often manifest as chronic conditions.

I have added new chapters on sudden cardiac death, congestive heart failure, peripheral artery

disease and aortic aneurysms, and venous thromboembolism and pulmonary embolism. Important new findings are discussed, such as the association of post-traumatic stress disorder with suicide and the emerging crisis of antibiotic resistance in tuberculosis and other chronic infections. Epidemiologic findings and references have been updated throughout this book.

Each chapter follows a similar format, with subsections describing diagnostic criteria, historical perspectives, the global burden of disease, population differences and time trends in incidence, prevalence, disability and mortality, mechanisms of pathogenesis, risk factors, preventive factors, and opportunities for disease prevention and control. Key epidemiologic studies and findings are presented in chronological order with supporting evidence and references selected to guide readers for further study. It is assumed that students and readers are building on a knowledge base of basic epidemiology and human biology. The text blends the traditional elements of epidemiology with human anatomy, physiology, and molecular biology. The text is accompanied by an online instructor’s manual with recommended questions and answers drawn from each of the chapters.

It is my hope that the text will provide a forum for examining current hypotheses regarding chronic disease epidemiology. Subsections of each chapter focus on controversial topics in the epidemiology of each disease. This format facilitates active student discussion of molecular mechanisms of disease pathogenesis and the relevant epidemiologic issues pertaining to the prevention and control of chronic diseases.

In essence, the new edition of this book, like the first, is an amalgamation of a long-standing continuum of the exchange of ideas and information with many colleagues in the fields of medicine, public health, epidemiology, biostatistics, genetics, pathology, and molecular biology. This new edition will continue to reflect my own experiences in medicine, epidemiology, and public health, and I am deeply indebted to mentors, colleagues, and particularly students who have contributed to my education, research, and teaching over the past four decades.

► What Is New and Improved?

Epidemiology of Chronic Disease: Global Perspectives, Second Edition presents the current epidemiology and global burden of each of the 56 major diseases. This new edition contains the most recent information available on the epidemiology of major cardiovascular diseases; cancers; respiratory, metabolic, and musculoskeletal conditions; and neurodegenerative diseases complete with updated figures, tables, and global maps. The section on cardiovascular and cerebrovascular disease includes four new chapters on the epidemiology of congestive heart failure, peripheral artery disease and aortic dissection, venous thromboembolism and pulmonary embolism, and sudden cardiac death. The new epidemiology of cancer section contains widely updated materials to provide in-depth information on cancers that affect 28 regions of the body.

- **New Chapters.** The new edition includes 13 new chapters to include more information on Epidemiology of Sudden Cardiac Death (Chapter 5), Epidemiology of Heart Failure (Chapter 7), Epidemiology of Aortic Aneurysm and Dissection (Chapter 8), and Epidemiology of Venous Thromboembolism and Pulmonary Embolism (Chapter 9). There are also nine new chapters on cancer epidemiology including Epidemiology of Laryngeal Cancer (Chapter 14), Epidemiology of Cancers of the Lip, Oral Cavity, and Pharynx (Chapter 15), Epidemiology of Cancer of the Corpus Uteri (Chapter 23), Epidemiology of Vaginal, Vulvar, and Anal Cancer (Chapter 25), Epidemiology of Testicular Cancer (Chapter 27), Epidemiology of Carcinoma of the External Male Genitalia (Chapter 28), Epidemiology of Cancers of the Thyroid and Parathyroid (Chapter 31), Epidemiology of Adrenal Cancer (Chapter 32), and Epidemiology of Nonmelanoma Skin Cancer (Chapter 34).
- **Global Burden of Disease.** This new edition incorporates the most recent data from the World Health Organization, the Institute of Health Metrics and Evaluation, the International Agency for Cancer Research, and other international organizations to characterize important global patterns and trends in the epidemiology of each disease. Updated world maps and figures are used to display global patterns and trends in disease prevalence, incidence, mortality, and disability-adjusted life years.
- **U.S. Burden of Disease.** Each chapter includes a section on the burden of disease in the U.S. population based on current data from the National Institutes of Health, the American Heart Association, the American Cancer Society, and other national organizations.
- **Risk Factors.** Published studies from the recent literature are discussed regarding new findings on risk factors and preventive factors that impact the pathogenesis of disease.
- **Pathogenesis.** Current mechanisms of pathogenesis of each disease are discussed and depicted in each chapter.
- **Disease Prevention and Control.** The most recent and effective programs of disease prevention and control are presented in each chapter.
- **Instructor Resources.** Instructors using the text will have online access to updated lecture slides, outlines, and test banks with answers for each chapter.


Randall E. Harris, MD, PhD

*Professor, Colleges of Public Health and Medicine
Director, Center of Molecular Epidemiology &
Environmental Health
Division of Epidemiology & Departments of
Pathology & Emergency Medicine
The Ohio State University Wexner Medical Center
Columbus, Ohio*

Contributors

Susanne K. Scott, PhD, MPH
Belgium, Wisconsin

Zachary M. Harris, MD, Fellow
Pulmonary, Critical Care and Sleep Medicine
Department of Internal Medicine
Yale School of Medicine
Yale University
New Haven, Connecticut



SECTION I

Epidemiologic Transition and Epidemiology of Cardiovascular Diseases

CHAPTER 1	Global Epidemiology of Chronic Diseases: The Epidemiologic Transition	3
CHAPTER 2	Global Epidemiology of Cardiovascular Disease . . .	27
CHAPTER 3	Epidemiology of Ischemic (Coronary) Heart Disease	37
CHAPTER 4	Epidemiology of Myocardial Infarction	57
CHAPTER 5	Epidemiology of Sudden Cardiac Death	75
CHAPTER 6	Epidemiology of Stroke (Cerebral Infarction)	85
CHAPTER 7	Epidemiology of Heart Failure	105

CHAPTER 8 Epidemiology of Aortic Aneurysm and Dissection 119

CHAPTER 9 Epidemiology of Venous Thromboembolism and Pulmonary Embolism 129

CHAPTER 10 Epidemiology of Hypertension 137

CHAPTER 1

Global Epidemiology of Chronic Diseases: The Epidemiologic Transition

► Global Pandemic of Chronic Diseases

A silent pandemic of chronic diseases is gradually enveloping the world population, spreading to all corners of the globe. This distinct spectrum of human afflictions is systemically replacing infectious and parasitic diseases as the leading cause of morbidity and mortality worldwide, thereby producing one of the greatest public health challenges of all time. According to global cause-specific mortality data reported by the *Institute of Health Metrics and Evaluation* non-communicable (chronic) disorders such as coronary heart disease, stroke, cancer, chronic obstructive pulmonary disease (COPD), diabetes mellitus type 2, neurodegenerative disease, and renal failure accounted for 39.5 million of the 54.7 million deaths (72%) for which a cause was identified during 2016 (Ritchie & Roser, 2018). This compares with 10.6 million deaths (19%) due to communicable (infectious) diseases, maternal, neonatal, and nutritional diseases, and 4.6 million deaths (8%) from injury including homicide, suicide, conflict, and terrorism. As shown in **FIGURE 1.1**, trends in the annual number of deaths in these three categories during 1990–2016 reflect a steady increase in annual deaths from noncommunicable diseases concurrent with a steady decline in annual deaths from

communicable, maternal, neonatal, and nutritional diseases, whereas the annual number of deaths from injury has remained stable (Ritchie & Roser, 2018; WHO, 2009a, 2017c).

The following excerpts from the 2008 WHO global report entitled *Preventing Chronic Diseases: A Vital Investment* capture the essence of the global pandemic of chronic diseases (Reprinted from WHO, 2008a).

“Chronic diseases are the leading causes of death and disability worldwide. Disease rates from these conditions are accelerating globally, advancing across every region and pervading all socioeconomic classes. The World Health Report 2002 “Reducing Risks, Promoting Healthy Life” indicates that the mortality, morbidity and disability attributed to the major chronic diseases currently account for almost 60% of all deaths and 43% of the global burden of disease. By 2020 their contribution is expected to rise to 73% of all deaths and 60% of the global burden of disease. Moreover, 79% of the deaths attributed to these diseases occur in the developing countries. Four of the most prominent chronic diseases, cardiovascular diseases (CVD), cancer, chronic obstructive pulmonary disease (COPD), and type 2 diabetes, are linked by common and preventable biological risk factors, notably high blood pressure, high blood cholesterol and overweight, and




FIGURE 1.1 Global Trends in Deaths from Noncommunicable and Communicable Diseases and Injuries, 1990–2016.

Data from WHO. (2009a). *World health statistics, 2009*. Geneva, Switzerland: WHO/WHO. (2017). *World health statistics, 2017*. Geneva, Switzerland: WHO; Ritchie, H., & Roser, M. (2018). "Causes of Death". Published online at OurWorldInData.org. Retrieved from <https://ourworldindata.org/causes-of-death> [Online Resource]

by related major behavioral risk factors: unhealthy diet, physical inactivity, and tobacco use. Action to prevent these major chronic diseases should focus on controlling these and other key risk factors in a well-integrated manner."

The global pandemic of chronic diseases has emerged in concert with the changing demography of the world population. Overall, the world birth rate exceeds the death rate, and the number of living individuals on the planet continues to increase. At the same time, more and more people are living to older ages thereby creating the phenomenon of "global aging." Aging populations are particularly evident in the industrialized and developed nations of the world, such as Japan, Italy, and Germany, where the proportion of elderly people (over 65 years of age) has increased from approximately 10% to 20% in the past half century (Hayutin, 2007). In large developing nations such as China and India, the proportion of elderly people is also expected to increase from current levels of about 5% to nearly 10% in the next few decades. In smaller underdeveloped nations where less than 5% of the people currently live beyond 65 years of age, population aging is also progressing, but at a slower pace. As a general consequence of the aging world population, long-term mechanisms of pathogenesis are more likely to cause disease late in life, thus resulting in vastly increased rates of chronic diseases, particularly among the elderly.

► Increase in World Population

As of July 1, 2017, The Department of Economic and Social Affairs of the United Nations Secretariat

estimated that the world population consisted of 7.55 billion living human beings (World Population Prospects, 2017). In that year, approximately 60 million people died and 140 million new babies were born, a net gain of 80 million people. Based upon projections of death rates and birth rates, the world population is expected to increase to nearly 9 billion people by the year 2040 (FIGURE 1.2).

► Aging of the World Population

The world population is not only increasing in number, but it is also growing older. Two demographic parameters are driving these phenomena: *longevity is increasing and the fertility rate is decreasing*. Studies at the World Health Organization (WHO, 2009a) and the Stanford Center of Longevity (Hayutin, 2007) clearly show that people around the world are living longer and women are having fewer children.

► Increasing Longevity (Life Expectancy)

The average life expectancy (also called longevity) for members of the world population born during 2010–2015 is 71 years (68 years for men and 73 years for women) (CIA, 2017). In the past half century, life expectancy has increased dramatically throughout the world, particularly in populations of developing nations. Since 1950, life expectancy in highly populated nations such as China and India has increased from approximately 40 years to nearly 70 years (FIGURE 1.3).




FIGURE 1.2 World Population.

Data from the United States Census Bureau. (2018). International Data Base. (estimates for 2020–2040 are based on curvilinear regression).




FIGURE 1.3 Longevity Trends in Selected Populations.

Data from United Nations Department of Economic and Social Affairs, Population Division. (2017). *United Nations World Population Prospects: 2017 revision*. New York, NY: United Nations. National Center for Health Statistics, 2017, USA.

In lesser developed nations, particularly those of central Africa where acute infectious and parasitic diseases prevail and greatly reduce the survival of children and young adults, life expectancy is much less, currently only about 50 years. In highly developed nations such as Japan, the United States, and European countries, longevity now approaches or surpasses 80 years and deaths are more likely due to chronic diseases of old age. The Japanese people currently enjoy the greatest longevity, about 82 years. Longevity in the United States currently stands at 79 years, only slightly higher than the average of the more developed nations (FIGURE 1.4).

Life expectancy is the average number of years that a newborn could expect to live if he or she were to pass through life *subject to the age-specific death rates of the population of interest for the past year.*

Derivation of life expectancy is usually presented as a “two-step” process. For large populations, life expectancy is calculated by *first constructing a life table and recording the number of deaths and survivors that occur in a given year for successive intervals of the life span.* The number of deaths and survivors and corresponding age-specific death rates are usually tabulated for ages 0–1 years, 1–5 years, and successive 5-year age groups for ages 5 and above. From these data, a second life table is then constructed to represent the entire mortality experience from birth to death for a hypothetical cohort of 100,000 infants born alive and subject to the age-specific death rates that prevail in the population of interest for a particular year. Using the data from this second life table for 100,000 hypothetical individuals, life expectancy is simply calculated as the average years of life for all members since birth




FIGURE 1.4 Global Longevity, 2011.

Data from CIA World Factbook, 2011 Estimates of Life Expectancy at Birth (Years).

(e.g., life expectancy = total years of life for all members of the life table divided by the total number of persons at birth, $Life\ Expectancy = \frac{\sum\ years\ of\ life}{100,000}$). Life expectancy (longevity) at birth is therefore the mean years of life for individuals based entirely on the age-specific death rates for the population and year of interest (Colton, 1974).

► Gender Differences in Longevity

Throughout the world, life expectancy (longevity) for women is 5–10 years greater than for men. With some exceptions in nations where high maternal death rates prevail due to lack of prenatal care, women have lower death rates and better survival at every age. In the industrialized world, improvements in prenatal care have reduced maternal mortality during the child-bearing years thereby widening the gender gap in longevity during much of the 20th century. For example, the gender divergence in longevity in the U.S. population gradually increased from about 2 years in 1900 to approximately 8 years in 1970, after which the difference shrank back to about 6 years, currently 81 years for women versus 75 years for men (**FIGURE 1.5**). The slight shrinkage of the U.S. gender gap during the past 40 years is believed to reflect equalizing smoking rates among men and women (Pampel, 2002).

The survival differential favoring females actually begins at conception. Only about 90% of male fetuses survive to birth compared to nearly 100% of female

fetuses. While precise causative factors for this disparity remain unclear, the relatively high rates of spontaneous abortions, miscarriages, and stillbirths among male fetuses could be due to hormonal incompatibilities of the male genotype in a milieu of female hormones such as estrogen and progesterone throughout gestation (Austad, 2006). At the other end of the life span, approximately 70% of individuals over 90 years of age are female, and remarkably, about 90% of centenarians (individuals over 100 years of age) are female (Perls, Hutter Silver, & Lauerman, 1999).

While no single factor can satisfactorily explain the clear survival advantage of women throughout life, certain environmental and biological differences are worth pointing out. The longer life span of women compared to men is undoubtedly related to gender differences in lifestyle. Despite the fact that men are, on average, bigger, stronger, faster, and more economically self-sufficient, their lifestyle choices and risky health behaviors obviously confer a clear survival advantage to women. In general, men have greater exposure to classical risk factors of disease such as tobacco and alcohol and, as a consequence, are more likely to die earlier from associated chronic conditions such as cardiovascular disease, lung cancer, chronic obstructive pulmonary disease, and cirrhosis of the liver. Men are also more likely to die from injuries, whether unintentional (motor vehicle or occupational accidents) or intentional (suicide, homicide, or war). Reciprocally, women have traditionally been the “*sentinels of health*” for their families and communities at large. Due to their instinctive “*nurturing maternal instinct*,” women tend to take better care




FIGURE 1.5 Life Expectancy, the United States, Women and Men.

Data from United Nations Department of Economic and Social Affairs, Population Division. (2017). *United Nations World Population Prospects: 2017 revision*. New York, NY: United Nations. National Center for Health Statistics, 2017, USA.

of themselves and make healthier lifestyle choices than men, thus contributing to their longer life span.

Hormonal differences between men and women may also influence their differences in lifestyle and longevity. Men are greater risk-takers than women, particularly during the years of young adulthood when circulating levels of testosterone are highest. The biological effects of androgens and estrogens differ dramatically. Androgens have vasoconstrictive and inflammatory effects in blood vessels consistent with higher rates of cardiovascular disease in men whereas estrogens exert opposite effects and are thus cardioprotective in women, particularly during their reproductive years (Blackman et al., 2002; Parker et al., 2009). Moreover, gender differences in the balance of estrogens and androgens appear to confer heightened immunity and more resistance to infectious and degenerative diseases in women throughout life (Austad, 2006).

► Aging and Disease

Aging is a complex process involving a decline in physiological processes that are essential for life. As humans age, there is heightened susceptibility to life-threatening acute and chronic diseases. A characteristic “death curve” is depicted in **FIGURE 1.6**. The data points represent approximate all-cause annual mortality rates estimated for successive 10-year age brackets for the U.S. population of 2002 (National Vital Statistics System, 2002). Note that the risk of death is elevated in the early years up to 5 years of age, after which there is a relatively long subtle increase in the risk of death until approximately 40 years of age, after which all-cause mortality exponentially rises for all successive age brackets.

Aging can thus be viewed as the general deterioration in human health over the life span generally associated with development of debilitating and

life-threatening disease processes. Indeed, aging has been defined as the spectrum of changes that render human beings progressively more likely to die (Medawar, 1952). As shown in **FIGURE 1.7**, the prevalence of major chronic diseases (arthritis, heart disease, cancer, diabetes mellitus type 2, and chronic obstructive pulmonary disease) rises exponentially with age. It is obvious that the phenotype of human aging is one in which practically any system, tissue, or organ can fail, resulting in debilitation and death (Austad, 1997; MacNee, Rabinovich, & Choudhury, 2014; Strehler, 1999). Nevertheless, it is important to stress that aging is not merely a collection of diseases. Rather, certain pathologic conditions progress in parallel with the aging process while others, such as asthma, remain constant or even decline late in life.

► Aging of Human Cell Populations

Aging is a complex and controversial subject. The aging phenomenon appears to be driven by deterioration in cellular health. The human body consists of tens of trillions of cells. This huge population of cells is divisible into subpopulations, each consisting of billions of cells that comprise certain anatomic structures, organs, and tissues. These component cell populations exist in a state of relative homeostasis performing the essential functions of life.

Studies of aging suggest that different cellular populations comprising the human body of a single individual do not all age at the same rate. Acceleration of the aging phenomenon in even one critical cell population may create a “weak link” for the entire system resulting in debilitation and death. However, as pointed out by Hayflick, the aging process does not share its elemental features with any particular disease




FIGURE 1.6 Characteristic Death Curve Modeled on the U.S. Population 2002.

Data from Aris, E. (2004). United States life tables, 2002. *National Vital Statistics Reports*, 53(6), 1–40.




FIGURE 1.7 Prevalence of Selected Chronic Conditions Expressed as Percentages, as a Function of Age for the U.S. Population (2002–2003 Dataset).

Data from National Center for Health Statistics, Data Warehouse on Trends in Health and Aging, 2003.

(Hayflick, 2007). This observation led him to state that, “the fundamental aging process is not a disease but it increases vulnerability to disease.” To paraphrase, aging may be the cause but not necessarily the effect of a disease process.

The preservation of homeostasis among populations of normally functioning cells in the human body depends primarily upon the balance of cell death and cell replacement. If cells die faster than they are replaced, then the progressively greater demands placed upon those cells that remain may eventually lead to pathologic changes and rapid deterioration in cellular health. Any one of multiple intrinsic and extrinsic factors capable of upsetting the balance of cell death and cell replacement may therefore have considerable impact on the aging phenomenon, particularly for those cell populations that do not

normally undergo cell division (e.g., neurons and mature muscle cells).

Programmed cell death (called apoptosis) and cell division are tightly regulated by genetic factors; nevertheless, both processes are also subject to modulation by extracellular as well as intracellular molecular factors. Aging may thus result from extrinsic or intrinsic factors that cause an accumulation of cellular and tissue damage, or alternatively, changes in gene expression related to DNA damage and somatic mutations, epigenetic factors such as methylation or acetylation of DNA, or structural modification of DNA by the intrinsic biological clock that regulates the number of cell divisions (e.g., telomere shortening in chromosomes) (Campisi, Kim, Lim, & Rubio, 2001). The etiology of the aging phenomenon therefore appears similar to most complex human traits. Aging is influenced by genetic and environmental factors that interact to produce significant phenotypic variability. Two key theories of aging are briefly discussed in the following sections: one involves the energy rich micro-environment of the cell and the other the genetically controlled biological clock of cell division.

► Free Radical Theory of Aging

More than half a century ago, Denham Harman developed the free radical theory of aging (Harman, 1956). His theory states that aging is a consequence of accumulating oxidative damage to cells and cellular components over time (reviewed in Beckman & Ames, 1998). Harman later extended his theory to include mitochondrial production of free radicals during normal cellular respiration (Harman, 1972).

Free radicals and oxidants, commonly called reactive oxygen species (ROS), are highly unstable




FIGURE 1.8 Free Radical Theory of Cell Damage, Aging, and Chronic Disease.

reactive molecules that can damage many vital cellular components (**FIGURE 1.8**). Rebecca Gerschman and colleagues discovered that ROS can originate from exogenous sources such as ultraviolet and ionizing radiation and were the first to suggest that free radicals are toxic agents (Gerschman, Gilbert, Nye, Dwyer, & Fenn, 1954).

ROS can be formed by exogenous processes such as irradiation and inflammation as well as normal cell metabolism. These short-lived molecules include superoxide, peroxide, hydroxyl radicals, and reactive nitrogen species such as peroxynitrite, all of which are unstable and readily react with DNA to cause a variety of structural genetic alterations including base pair mutations, rearrangements, deletions, insertions, and DNA sequence amplification. While DNA mutations, alterations, and chromosomal abnormalities increase with age in mice and other laboratory animals, damage to nuclear diploid DNA by ROS remains an unproven cause of aging (Ames, Shigenaga, & Hagen, 1993).

Oxidative phosphorylation is responsible for energy production within the mitochondria of virtually all cells. Since this process continually produces ROS such as superoxide and hydrogen peroxide, and since mitochondria possess haploid DNA unprotected by histones, many advocates of the free radical theory of aging consider that oxidative damage to mitochondria and the mitochondrial DNA has a primary role in the aging process (Barja & Herrero, 2000; de Grey, 1997; Harman, 1972; Linnane, Marzuki, Ozawa, & Tanaka, 1989).

Certain nutraceutical agents have gained favor as free radical scavengers that offer some protection against oxidation and the formation of ROS. These include ascorbic acid (vitamin C), tocopherol (vitamin E), carotenes, melatonin, and antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase that are capable of degrading ROS into inert compounds (Ames, Cathcart, Schwiers, & Hochstein, 1981).

► Telomere Shortening and Aging

Cell division is an extraordinarily precise process that gives rise to daughter cells that have *almost* exactly the same genetic constitution as their progenitors. However, with every cell division, there is incomplete duplication of the chromosomal tips (called telomeres). Successive cell divisions therefore result in shortening of chromosomes until a point is reached where the daughter cells are no longer capable of dividing (called the “*Hayflick Limit*” after its discoverer). Since cells that reach their Hayflick Limit cannot replicate, the balance of cell replication and cell death is interrupted and cellular health may deteriorate. This is the basis of the *Telomere Theory of Aging*; namely, as an ever-increasing percentage of cells reach their Hayflick Limit and are unable to reproduce, then defense, maintenance, and repair of the body becomes increasingly impaired. Thus, telomere attrition due to the Hayflick Limit could account for most of the decline in functional efficiency of cell populations and increases in vulnerability to chronic diseases that characterize the aging phenomenon (de Magalhaes & Faragher, 2008; Hayflick, 1985, 2007).

► Declining Fertility Rate in Women

Over the past half century, the worldwide fertility rate (the average number of births per woman during the childbearing years) has been cut in half, from 5.0 in the 1950s to 2.5 in the 21st century (**FIGURE 1.9**). The decline in fertility rates has been sharpest in the most populous nations such as China, India, and Russia. For example, the fertility rate in China, which has the world’s largest population (1.38 billion), decreased from more than 6 in 1970 to 1.6 births per woman in 2017, well below the worldwide